Chemo-Radio-Immunotherapy for NSCLC III: ESR/ATS Thresholds for DL
DLCO
ESR/ATS thresholds
NSCLC stage III
chemoradiotherapy
durvalumab
immunotherapy
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
25 Mar 2023
25 Mar 2023
Historique:
received:
03
02
2023
revised:
21
03
2023
accepted:
23
03
2023
medline:
14
4
2023
entrez:
13
4
2023
pubmed:
14
4
2023
Statut:
epublish
Résumé
Durvalumab following chemoradiotherapy (CRT) for non-small cell lung cancer stage III has become the standard of care (SoC) in the past few years. With this regimen, 5-year overall survival (OS) has risen to 43%. Therefore, adequate pulmonary function (PF) after treatment is paramount in long-term survivors. In this respect, carbon monoxide diffusing capacity (DL One hundred and twelve patients with histologically confirmed NSCLC III treated between 2015/10 and 2022/03 were eligible for this study. Patients received two cycles of platinum-based induction chemotherapy followed by high-dose radiotherapy (RT). As of 2017/09, durvalumab maintenance therapy was administered for one year. The clinical endpoints were based on the thresholds jointly published by the European Respiratory Society (ERS) and the American Thoracic Society (ATS). Pre-treatment DL Patients with a pre-treatment DL The current analysis revealed that DL
Identifiants
pubmed: 37046627
pii: cancers15071966
doi: 10.3390/cancers15071966
pmc: PMC10092995
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Clin Oncol. 2005 Sep 1;23(25):5910-7
pubmed: 16087956
N Engl J Med. 2017 Nov 16;377(20):1919-1929
pubmed: 28885881
J Natl Compr Canc Netw. 2021 Mar 02;19(3):254-266
pubmed: 33668021
Int J Radiat Oncol Biol Phys. 2022 Jul 1;113(3):561-569
pubmed: 35227790
Respiration. 2013;86(2):100-8
pubmed: 23154264
Eur Respir J. 2004 Jun;23(6):932-46
pubmed: 15219010
Cancers (Basel). 2022 Jun 30;14(13):
pubmed: 35804997
J Thorac Oncol. 2018 Dec;13(12):1930-1939
pubmed: 30267842
Oncoimmunology. 2021 Aug 10;10(1):1959979
pubmed: 34408921
J Clin Oncol. 2010 May 1;28(13):2181-90
pubmed: 20351327
Ann Oncol. 2017 May 01;28(5):1117-1123
pubmed: 28327906
Int J Radiat Oncol Biol Phys. 2009 Jul 1;74(3):781-9
pubmed: 19084355
Int J Radiat Oncol Biol Phys. 2015 Jun 1;92(2):423-9
pubmed: 25817531
J Thorac Oncol. 2022 Dec;17(12):1415-1427
pubmed: 35961520
J Clin Oncol. 1999 Sep;17(9):2692-9
pubmed: 10561343
J Surg Oncol. 2009 Dec 15;100(8):703-7
pubmed: 19798693
Respir Physiol Neurobiol. 2003 Nov 14;138(2-3):115-42
pubmed: 14609505
J Clin Oncol. 2022 Apr 20;40(12):1301-1311
pubmed: 35108059
Am Rev Respir Dis. 1989 Dec;140(6):1818-22
pubmed: 2604306
Eur Respir J. 2005 Nov;26(5):948-68
pubmed: 16264058
Radiat Oncol. 2013 Mar 05;8:49
pubmed: 23497555
J Natl Cancer Inst. 2011 Oct 5;103(19):1452-60
pubmed: 21903745
Lung Cancer. 2022 Dec;174:174-185
pubmed: 35717343
J Thorac Cardiovasc Surg. 1995 Feb;109(2):275-81; discussion 281-3
pubmed: 7853881
Thorac Cancer. 2020 Feb;11(2):369-378
pubmed: 31855325
Int J Radiat Oncol Biol Phys. 2005 Jul 1;62(3):639-44
pubmed: 15936539
N Engl J Med. 2018 Dec 13;379(24):2342-2350
pubmed: 30280658
Diagnostics (Basel). 2022 Apr 19;12(5):
pubmed: 35626183
J Thorac Cardiovasc Surg. 1999 Mar;117(3):581-6; discussion 586-7
pubmed: 10047663
Eur Respir J. 2017 Jan 3;49(1):
pubmed: 28049168
BMC Pulm Med. 2018 Oct 11;18(1):159
pubmed: 30305051
Clin Lung Cancer. 2019 Nov;20(6):442-450.e4
pubmed: 31446020
Lung Cancer. 2004 Oct;46(1):87-98
pubmed: 15364136
Lung Cancer. 2004 Feb;43(2):159-66
pubmed: 14739036
JAMA Oncol. 2016 Dec 01;2(12):1607-1616
pubmed: 27540850
Lancet Oncol. 2015 Feb;16(2):187-99
pubmed: 25601342
Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S70-6
pubmed: 20171521